Organization | SocraMetrics GmbH

SocraMetrics GmbH Report issue

For profit Phase 1 Phase 2

Founded: Erfurt Germany (2007)

Organization Overview

First Clinical Trial

2009

NCT00889850

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

SocraMetrics GmbH

Active Ingredients

Drugs in Phase 2 Trials (1)

tmp001 (1 trial)

Drugs in Phase 1 Trials (8)

cannabidiol (Epidiolex) (1 trial)

deferiprone (ferriprox) (1 trial)

esflurbiprofen (1 trial)

esomeprazole (nexium) (1 trial)

flurbiprofen (ansaid) (1 trial)

ibuprofen (motrin) (1 trial)

nifedipine (procardia) (1 trial)

rivastigmine (exelon) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 9